Multikine® Therapy Treats Newly Diagnosed Head and Neck Cancer Patients Before They Undergo Surgery, Radiation, or Chemotherapy CEL-SCI Corporation is a publicly-traded (NYSE: CVM) Phase III cancer immunotherapy company with operations in the Baltimore area. CEL-SCI develops immunotherapy products for the treatment of cancer and infectious diseases, based on the premise of boosting patients’ immune systems while they are still intact to maximize the likelihood of survival. CEL-SCI’s lead investigational immunotherapy Multikine® treats patients who are newly diagnosed with head and neck cancer before they have undergone surgery, radiation, or chemotherapy. Multikine® has received an Orphan Drug designation from the…
Author: Brett Johnson
Aphios Pharma is Now Developing Cannabis-Based Treatment for Opioid Addition Aphios Corporation is a Woburn, MA-based, clinical-stage biotechnology company that is developing green enabling technology platforms to improve drug discovery, manufacturing, nanotechnology drug delivery, and pathogenic safety. Aphios is delivering enhanced therapeutic products to improve quality-of-life and treat chronic diseases in an environmentally-sustainable manner. Utilizing medicinal plants and marine organisms, Aphios develops therapies that treat cancer as a chronic rather than acute disease, providing less toxic and mostly plant-based natural drugs. Aphios’ nanoformulations of Taxol® and Taxotere® may be used in acute settings until long-term preventative solutions are developed, and…
Therapy Targets AFP Receptors Found in Over 80 Percent of Cancer Cells Alpha Cancer Technologies Inc. (ACT) is a Toronto-based clinical-stage biotechnology company that is developing drugs for oncology and auto-immune disease indications. Alpha Cancer Technologies’ products include Alpha-Fetoprotein (AFP), a human protein produced by the embryo during fetal development; an immunotherapy platform; and a targeted chemotherapy platform. The company offers non-covalently-bound chemotherapy (paclitaxel and thapsigargin) and chemically-linked chemotherapy, such as maytansine. ACT uses recombinant human alpha-fetoprotein to selectively target cancer cells and deliver toxic chemotherapeutic agents exclusively to those cells. Alpha Cancer Technologies owns exclusive worldwide rights to the…
RNA Disruption Assay™ Test Can Determine Degree of Ribosomal RNA Disruption During Chemotherapy Rna Diagnostics Inc. is a Toronto-based early-stage molecular diagnostics company that is developing medical diagnostic tools to assist in the management of cancer. The company’s first product, RNA Disruption Assay™ (RDA™), is a novel test that helps oncologists to rapidly assess the effectiveness of cancer chemotherapy. The RDA™ test can determine whether chemotherapy is working effectively in an individual patient early in treatment, thereby enabling more effective clinical decision-making. RDA™ utilizes a needle biopsy taken during cancer treatment to determine the degree of ribosomal RNA (rRNA) disruption,…
“20/20 Hindsight” Platform Improves Accuracy of Most Widely Used Cancer Biomarkers 20/20 GeneSystems, Inc. is a Rockville, MD-based, digital diagnostics company focused on reducing cancer mortality through early detection. 20/20 GeneSystems is pioneering a novel approach to cancer detection, called “20/20 Hindsight”, that uses continuous machine learning to utilize large patient data sets of biomarker values to evaluate clinical factors such as age, gender, and smoking history for early cancer detection. 20/20 GeneSystems’ “20/20 Hindsight” platform can aid in the early detection of cancer by improving the accuracy of the most widely used cancer biomarkers. 20/20 GeneSystems was founded in…
Q1© Platform Takes Unique Approach to Isolation and Interrogation of Individual Cancer Cells QuantumCyte is a Silicon Valley-based early-stage biotechnology company that is developing a unique drug assay system. QuantumCyte’s single-cell analysis system, known as Q1©, can predict drug efficacy in a way that is rapid, non-invasive, and accurate. Q1© is the first high-throughput single-cell analysis platform to correlate gene expression with phenotypic data. The Q1© platform leverages QuantumCyte’s ArraySeQ© chemistry and a novel reagent exchange system to enable high-efficiency transcriptome capture, low running costs, and new applications in systems biology, drug discovery, and predictive medicine. QuantumCyte’s high-density dome array…
CAR T Cell Therapy May Change Cancer Patients’ Own Weak T Cells into “Bionic Killing Machines” Aurora Biopharma is a Cambridge, MA-based, clinical-stage company that is developing state-of-the-art cancer immunotherapy, utilizing a form of adoptive cell transfer called Chimeric Antigen Receptor (CAR) T Cell Therapy. The therapy genetically edits patients’ T cells to express a CAR specific to the type of cancer present, which enables targeted killing of cancer cells. The U.S. Food & Drug Administration has awarded Aurora Biopharma’s CAR T Cell Therapy with its Breakthrough Therapy Designation for the therapy’s treatment of pediatric and adult acute lymphoblastic leukemia…